Morten K. Jensen

Roskilde, Denmark

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 18 publications

NSAID consumption and risk of acute myeloid leukemia: a national population-based case-control study.

NSAID consumption and risk of acute myeloid leukemia: a national population-based case-control study.

Journal: Cancer management and research

Published: November 23, 2018

Autoimmune diseases, infections, use of antibiotics and the risk of acute myeloid leukaemia: a national population-based case-control study.

Autoimmune diseases, infections, use of antibiotics and the risk of acute myeloid leukaemia: a national population-based case-control study.

Journal: British journal of haematology

Published: November 19, 2017

Improved outcome in acute myeloid leukemia patients enrolled in clinical trials: A national population-based cohort study of Danish intensive chemotherapy patients.

Improved outcome in acute myeloid leukemia patients enrolled in clinical trials: A national population-based cohort study of Danish intensive chemotherapy patients.

Journal: Oncotarget

Published: June 21, 2016

A 7-Gene Signature Depicts the Biochemical Profile of Early Prefibrotic Myelofibrosis.

A 7-Gene Signature Depicts the Biochemical Profile of Early Prefibrotic Myelofibrosis.

Journal: PloS one

Published: February 08, 2016

Interferon-α induces marked alterations in circulating regulatory T cells, NK cell subsets, and dendritic cells in patients with JAK2V617F-positive essential thrombocythemia and polycythemia vera.

Interferon-α induces marked alterations in circulating regulatory T cells, NK cell subsets, and dendritic cells in patients with JAK2V617F-positive essential thrombocythemia and polycythemia vera.

Journal: European journal of haematology

Published: September 14, 2015

Expansion of circulating CD56bright natural killer cells in patients with JAK2-positive chronic myeloproliferative neoplasms during treatment with interferon-α.

Expansion of circulating CD56bright natural killer cells in patients with JAK2-positive chronic myeloproliferative neoplasms during treatment with interferon-α.

Journal: European journal of haematology

Published: July 29, 2014

Whole blood transcriptional profiling reveals deregulation of oxidative and antioxidative defence genes in myelofibrosis and related neoplasms. Potential implications of downregulation of Nrf2 for genomic instability and disease progression.

Whole blood transcriptional profiling reveals deregulation of oxidative and antioxidative defence genes in myelofibrosis and related neoplasms. Potential implications of downregulation of Nrf2 for genomic instability and disease progression.

Journal: PloS one

Published: April 24, 2014

Circulating YKL-40 in myelofibrosis a potential novel biomarker of disease activity and the inflammatory state.

Circulating YKL-40 in myelofibrosis a potential novel biomarker of disease activity and the inflammatory state.

Journal: European journal of haematology

Published: March 26, 2014

Circulating YKL-40 in patients with essential thrombocythemia and polycythemia vera treated with the novel histone deacetylase inhibitor vorinostat.

Circulating YKL-40 in patients with essential thrombocythemia and polycythemia vera treated with the novel histone deacetylase inhibitor vorinostat.

Journal: Leukemia research

Published: February 20, 2014

Transcriptional profiling of whole blood identifies a unique 5-gene signature for myelofibrosis and imminent myelofibrosis transformation.

Transcriptional profiling of whole blood identifies a unique 5-gene signature for myelofibrosis and imminent myelofibrosis transformation.

Journal: PloS one

Published: October 02, 2013

Data quality in the Danish National Acute Leukemia Registry: a hematological data resource.

Data quality in the Danish National Acute Leukemia Registry: a hematological data resource.

Journal: Clinical epidemiology

Published: September 17, 2013

No evidence of survival benefit with addition of gemtuzumab ozogamicin to standard medical research council induction chemotherapy.

No evidence of survival benefit with addition of gemtuzumab ozogamicin to standard medical research council induction chemotherapy.

Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology

Published: March 27, 2013

Showing 1-12 of 18

Last Updated: 09/26/2026